A detailed understanding of the molecular changes associated with drug resistance is critical for identifying prognostic markers and additional targets to circumvent drug resistance and ultimately benefit FLT3-mutant AML patients with durable therapeutic responses. Here, FLT3 is linked to acute myeloid leukemia.